Eurosurv. Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022

[tetano]

• Leanne PM van Leeuwen[SUP]1,2,*[/SUP] , Marc C Shamier[SUP]1,*[/SUP] , Babs E Verstrepen[SUP]1[/SUP] , Hannelore M Götz[SUP]3[/SUP] , Katharina S Schmitz[SUP]1[/SUP] , Najlae Akhiyate[SUP]1[/SUP] , Koen Wijnans[SUP]1[/SUP] , Susanne Bogers[SUP]1[/SUP] , Martin E van Royen[SUP]4[/SUP] , Eric CM van Gorp[SUP]1,2[/SUP] , Marion PG Koopmans[SUP]1[/SUP] , Rory D de Vries[SUP]1,**[/SUP] , Corine H GeurtsvanKessel[SUP]1,**[/SUP] , Luca M Zaeck[SUP]1[/SUP]

In response to the mpox outbreak in 2022 and 2023, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as JYNNEOS or Imvanex) was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralising antibodies waned to undetectable levels 1 year post vaccination in at-risk individuals who received two doses of MVA-BN administered subcutaneously with an interval of 4 weeks, without prior smallpox or mpox vaccination. Continuous surveillance is essential to understand the impact of declining antibody levels.
​

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.38.2400575